section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: BP, tachycardia

EENT: nasopharyngitis

GI: constipation, diarrhea, nausea

GU: urinary tract infection

Neuro: dizziness, headache

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Overactive Bladder

Renal Impairment

Hepatic Impairment

Neurogenic Detrusor Overactivity

Renal Impairment

Renal Impairment

Renal Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

US Brand Names

Myrbetriq

Action

  • Acts as a selective beta-3 adrenergic agonist.
  • Increases bladder capacity by relaxing detrusor smooth muscle during storage phase of bladder fill-void cycle.
Therapeutic effects:
  • Decreased symptoms of OAB.
  • Improved bladder capacity in neurogenic detrusor overactivity.

Classifications

Therapeutic Classification: urinary tract antispasmodics

Pharmacologic Classification: beta-adrenergic agonists

Pharmacokinetics

Absorption: 29–35% absorbed following oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.

Half-Life: Adults: 50 hr; Children: 26–31 hr.

Time/Action Profile

(effects on bladder)

ROUTEONSETPEAKDURATION
POunknown3–4 hr24 hr

Blood level.



Patient/Family Teaching

Pronunciation

mye-ra-BEG-ron